Pityriasis rosea–like eruption during treatment with imatinib mesylate: Description of 3 cases - 21/08/11
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Pavia, Italy
Abstract |
Imatinib mesylate (IM) represents the first-line treatment for chronic myeloid leukemia (CML). We hereby relate 3 cases of an IM-induced pityriasis rosea (PR)-like cutaneous eruption. Patients developed an erythematous, slightly pruritic, macular skin eruption, with many lesions having a peripheral collarette of desquamation, confined to the trunk, limbs, and arms with a vaguely dermatomal diffusion. The histologic findings suggested a reactive process to the drug. Full dermatological recovery was obtained after IM discontinuation, but lesions reappeared upon restoring therapy, suggesting the drug-related nature of the rash. To our knowledge this is the first reported PR-like cutaneous eruption to IM.
Le texte complet de cet article est disponible en PDF.Plan
Supported by Stiefel Laboratories. Funding sources: None. Conflicts of interest: None identified. |
Vol 53 - N° 5S
P. S240-S243 - novembre 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?